Dr Simon Crabb speaks to ecancer in an online interview for ASCO GU 2022 about the ATLANTIS trial: A phase II, randomised, multicentre, double-blind study evaluating maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma.

He begins by explaining that the patients' tumour samples underwent biomarker testing with the results leading to the allocation of a different treatment.

Each treatment option served as a separate phase II trial with rucaparib being analysed here.

Dr Crabb reports that patients that received rucaparib had a median PFS of 35.3 weeks compared to 15.1 weeks with placebo and believes that the positivity in the results indicate the need for further testing in this area.